Search

Background: Prognosis following a diagnosis of invasive epithelial ovarian cancer is poor. Some studies have suggested modifiable behaviors, like diet, are associated with survival but the evidence is inconsistent., Objective: To pool data from studies conducted around the world to evaluate the relation between dietary indices, foods, and nutrients from food sources and survival after a diagnosis of ovarian cancer., Methods: This analysis from the Multidisciplinary Ovarian Cancer Outcomes Group within the Ovarian Cancer Association Consortium included 13 studies with 7,700 individuals with ovarian cancer, who completed food-frequency questionnaires regarding their pre-diagnosis diet. Adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for associations with overall survival were estimated using Cox proportional hazards models., Results: Overall, there was no association between any of the seven dietary indices (representing pre-diagnosis diet) evaluated and survival; however, associations differed by tumor stage. While there were no consistent associations among those with advanced disease, among those with earlier stage (local/regional) disease, higher scores on the alternate Healthy Eating Index (aHR Quartile 4 versus 1 = 0.66, 95% CI=0.50, 0.87), Healthy Eating Index-2015 (aHR 0.75; 95% CI=0.59, 0.97) and alternate Mediterranean diet (aHR 0.76; 95% CI=0.60, 0.98) were associated with better survival. Better survival was also observed for individuals with early-stage disease who reported higher intakes of dietary components that contribute to the healthy diet indices (aHR for Q4 versus Q1: vegetables 0.71; 95% CI=0.56, 0.91), tomatoes (aHR 0.72; 95% CI=0.57, 0.91) and nuts and seeds (aHR 0.71; 95% CI=0.55, 0.92). In contrast, there were suggestions of worse survival with higher scores on two of the three inflammatory indices and higher intake of trans-fatty acids., Conclusions: Adherence to a more heathy, less inflammatory diet may confer a survival benefit for individuals with early-stage ovarian cancer., Competing Interests: Declaration of Competing Interest ☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Penelope M Webb reports a relationship with AstraZeneca Australia that includes: funding grants. Membership of an Advisory Board for Pfizer to enhance minoritized and underrepresented populations in clinical trials, unrelated to this study (EVB). If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2025. Published by Elsevier Inc.)